e-learning
resources
Berlin 2008
Monday, 06.10.2008
Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is standardized treatment appropriate for non-XDR multiple drug resistant TB?
P. Tabarsi, P. Baghaei, P. Farnia, M. Kazempour, S. Jalali, M. Masjedi, A. Velayati (Tehran, Islamic Republic Of Iran)
Source:
Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Session:
Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Session type:
Thematic Poster Session
Number:
2550
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Tabarsi, P. Baghaei, P. Farnia, M. Kazempour, S. Jalali, M. Masjedi, A. Velayati (Tehran, Islamic Republic Of Iran). Is standardized treatment appropriate for non-XDR multiple drug resistant TB?. Eur Respir J 2008; 32: Suppl. 52, 2550
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005
MDR-TB and XDR-TB: drug resistance and treatment outcomes
Source: Eur Respir J 2009; 34: 778
Year: 2009
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB)
Source: Eur Respir J 2003; 22: Suppl. 45, 555s
Year: 2003
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
MDR TB treatment in prison
Source: Eur Respir J 2002; 20: Suppl. 38, 614s
Year: 2002
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Source: Eur Respir J 2012; 39: 956-962
Year: 2012
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Artificial pneumothorax in the treatment of multi drug resistant tuberculosis (MDR TB)
Source: Eur Respir J 2006; 28: Suppl. 50, 586s
Year: 2006
Treating extensively drug resistant tuberculosis (XDR-TB) in India
Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2008
Why did they get XDR TB ?
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Source: Eur Respir J 2009; 34: 1492-1494
Year: 2009
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept